BIOL: BIOLASE, Inc. Stock

SIC 3843 – Dental Equipment and Supplies

Valuation
Market Cap ($M) 4.88
Enterprise Value ($M) 14.56
Book Value ($M) 1.96
Book Value / Share 0.06
Price / Book 2.49
NCAV ($M) -8.28
NCAV / Share -0.25
Price / NCAV -0.59

Profitability (mra)
Return on Invested Capital (ROIC) -1.17
Return on Assets (ROA) -0.49
Return on Equity (ROE) -2.53

Liquidity (mrq)
Quick Ratio 0.68
Current Ratio 1.26

Balance Sheet (mrq) ($M)
Current Assets 24.86
Assets 35.10
Liabilities 33.15
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 49.16
Operating Income -17.94
Net Income -20.63
Earnings Per Share Diluted n/a
Earnings Per Share Basic n/a

Cash Flow Statement (mra) ($M)
Cash From Operations -14.09
Cash from Investing -1.13
Cash from Financing 17.43

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)
Change
(%)
02-23 13G S.H.N. Financial Investments Ltd. 9.90
02-21 13G Lind Global Fund II LP 9.90 12,820.74
02-14 13G/A Lytton Laurence W 0.60
02-14 13G Anson Funds Management LP 8.10
10-10 13G/A Krefta Edson Roberto 10.00 51.02

Top 13F Investors Shares
(1000)
Change
(%)
Value
($1000)
Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-03-21 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K
2023-11-09 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q
2023-08-10 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q
2023-05-11 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2024-04-17 449,193 1,402,577 32.03
2024-04-16 159,698 37,333 427.77
2024-04-15 316,656 137,308 230.62
2024-04-12 263,619 87,026 302.92

(click for more detail)

Similar Companies
AXGN – AxoGen, Inc. BBLG – Bone Biologics Corporation
BEAT – HeartBeam, Inc. BJDX – Bluejay Diagnostics, Inc.
BLAC – Bellevue Life Sciences Acquisition Corp.


Financial data and stock pages provided by
Fintel.io